Perspective Therapeutics’ (CATX) “Outperform” Rating Reaffirmed at Wedbush

Posted by Brian Himes on Sep 15th, 2026

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report)‘s stock had its “outperform” rating reiterated by Wedbush in a report issued on Tuesday, Benzinga reports. They presently have a $11.00 price objective on the stock. Wedbush’s target price indicates a potential upside of 297.69% from the company’s previous close.

CATX has been the subject of several other reports. Bank of America reduced their price target on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. BMO Capital Markets set a $11.00 price target on Perspective Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Finally, Piper Sandler decreased their price target on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $11.50.

View Our Latest Research Report on CATX

Perspective Therapeutics Price Performance

Shares of CATX opened at $2.77 on Tuesday. Perspective Therapeutics has a fifty-two week low of $1.96 and a fifty-two week high of $6.16. The business has a 50-day moving average of $3.08 and a 200 day moving average of $3.71.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.09 million. On average, research analysts expect that Perspective Therapeutics will post -0.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Commodore Capital LP purchased a new position in shares of Perspective Therapeutics during the 1st quarter worth $26,424,000. Avidity Partners Management LP raised its holdings in Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after purchasing an additional 2,839,266 shares during the period. Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics by 954.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after purchasing an additional 2,864,582 shares during the period. Spruce Street Capital LP purchased a new position in Perspective Therapeutics during the first quarter valued at $10,955,000. Finally, Yu Fan purchased a new position in Perspective Therapeutics during the first quarter valued at $4,401,000. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

(Get Free Report)

Perspective Therapeutics, Inc is a clinical-stage biotechnology company developing precision-targeted radiopharmaceuticals for the treatment of cancer. The company focuses on therapies that combine tumor-targeting molecules with radioactive isotopes designed to deliver radiation directly to malignant cells while limiting exposure to surrounding healthy tissue.

Perspective Therapeutics’ proprietary VMT platform is intended to support the development of both therapeutic and diagnostic radiopharmaceuticals.